Congestive Heart Failure (CHF) Treatment Devices Market Size by Product, End-Users, Region – Segment-Level Market Assessment, Growth Opportunity Analysis, Competitive Mapping & Forecast to 2034
Overview
Congestive Heart Failure (CHF) Treatment Devices Market is expected to grow at a CAGR of 5.5% during the forecast period. Congestive Heart Failure (CHF) Treatment Devices Market is expected to reach US$ 6.75 Mn. by 2034.
Congestive Heart Failure (CHF) Treatment Devices Market Overview:
Congestive heart failure (CHF) is a disorder in which the heart muscles' capacity to pump enough blood is impaired. Shortness of breath, exhaustion, and leg swelling are all symptoms of this illness. As a result, it's critical to control heart failure with the help of numerous devices available on the market, such as defibrillators and pacemakers.
Congestive Heart Failure (CHF) Treatment Devices Market Size, Growth & Share Analysis
To know about the Research Methodology :- Request Free Sample Report
Congestive Heart Failure (CHF) Treatment Devices Market Dynamics:
Rising prevalence of cardiac disorders is the major factor contributing to the market growth.
The failure of the ventricles to pump a sufficient volume of blood to the bodily organs marks the beginnings of CHF. This causes fluid to accumulate in the lungs, abdomen, liver, and lower body. Pacemakers, cardiac resynchronization treatment (CRT), implanted cardioverter defibrillators (ICDs), and ventricular assist devices are among the technologies used to treat CHF. The growing frequency of cardiovascular disorders, technological improvements, and the rising number of cardiovascular surgeries are driving the market for congestive heart failure (CHF) therapy devices.
Other important factors linked to the development of CVDs include sedentary lifestyles, junk food consumption, and mental stress. According to the World Health Organization, cardiovascular disease is the leading cause of death worldwide in 2019, claiming the lives of an estimated 17.9 million people each year. As a result, the large target group has a positive impact on the treatment of congestive heart failure. Globally, the growing geriatric population is leading to an increase in CVD cases.
To increase market share, market players are focused on new growth strategies such as product launches, developments, mergers, and acquisitions. For example, Abbott Laboratories' HeartMate 3 Left Ventricular Assist Device (LVAD) was approved by the US Food and Drug Administration (FDA) in October 2018 for the treatment of heart failure. In developing markets, there is likely to be a large unmet treatment need for congestive heart failure. High equipment costs and unfavourable reimbursement rules are two concerns that could stymie the congestive heart failure treatment market's revenue growth.
The report has profiled sixteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.
Congestive Heart Failure (CHF) Treatment Devices Market Segment Analysis:
The Congestive Heart Failure (CHF) Treatment Devices Market is segmented on the basis of Product and End-Users.
Based on Product, the Implantable pacemakers segment is expected to account for significant market share xx% by 2034. An implantable pacemaker is a device that regulates cardiac rhythm using electrical impulses. An internal pacemaker has electrodes that are implanted in the heart and electronic circuitry and a power supply that is inserted within the body. According to a study published in the Journal of Arrhythmia in July 2020 by Ana C Gonzales-Luna et al., the COVID-19 pandemic resulted in a 73% reduction in pacemaker implants and a 78% reduction in de-novo pacemaker implants in patients diagnosed with complete or high-grade atrioventricular block, regardless of the aetiology. The growth of the implantable pacemakers segment is being fuelled by an increase in cardiovascular patients, as well as an increase in the geriatric population, reimbursement coverage, and technological advancements such as exclusive algorithms that accurately detect and reduce the risk of atrial fibrillation.
The Implantable Cardioverter Defibrillators segment is expected to grow at a significant CAGR of xx% throughout the forecast period. Implantable Cardioverter Defibrillators (ICDs) have a sizable market share thanks to their capacity to perform three main functions: defibrillation, cardioversion, and cardiac pacing. In 2019, the ICD category, which is divided into two types: transvenous and subcutaneous, had a sizable market share.
Congestive Heart Failure (CHF) Treatment Devices Market Regional Insights:
North America is expected to dominate the market during forecast years.
Increased demand for congestive heart failure (CHF) therapy, rising prevalence of target illnesses, high healthcare spending, and increased population awareness about treatment device availability are some of the reasons driving market growth in the North American area. COVID-19 individuals with an underlying heart problem are still more likely to become critically unwell, according to the Centres for Disease Control and Prevention (CDC). In addition, supportive illness awareness activities are expected to assist the market for cardiovascular devices in the North American area. Mexico, for example, joined the HEARTS project in 2020 to improve primary health care for cardiovascular illnesses. As a result of the aforementioned factors, the market in North America is likely to rise at a rapid pace over the forecast years.
The report also helps in understanding Global Congestive Heart Failure (CHF) Treatment Devices Market dynamics, structure by analyzing the market segments and project the Global Congestive Heart Failure (CHF) Treatment Devices Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Congestive Heart Failure (CHF) Treatment Devices Market make the report investor’s guide.
Congestive Heart Failure (CHF) Treatment Devices Market Recent Industry Developments
| Date | Company | Development | Impact |
|---|---|---|---|
| 23 March 2026 | Medtronic PLC | Medtronic received U.S. FDA approval for an expanded indication for its OmniaSecure defibrillation lead to be placed in the left bundle branch area for conduction system pacing. | This approval provides clinicians with the world's smallest-diameter, lumenless lead to deliver left bundle branch optimized cardiac resynchronization therapy (LOT-CRT) for heart failure patients. |
| 27 February 2026 | Abbott | Abbott secured U.S. FDA approval for its CardioMEMS HERO device, a next-generation pulmonary artery pressure reader designed for remote heart failure management. | The novel, portable design enhances patient engagement and enables clinicians to detect early hemodynamic changes to prevent heart failure hospitalizations. |
| 10 December 2025 | Impulse Dynamics PLC | Impulse Dynamics secured a strategic financing package to fuel global commercialization and clinical growth for its Optimizer Smart cardiac contractility modulation (CCM) system. | The funding accelerates adoption of implantable CCM therapy to improve quality of life and exercise tolerance in symptomatic heart failure patients. |
| 09 October 2025 | SQ Innovation Inc. | SQ Innovation received U.S. FDA approval for Lasix ONYU, a drug-device combination combining a novel high-concentration furosemide formulation with a small subcutaneous infusor for home edema treatment in chronic heart failure patients. | The approval offers a cost-effective alternative to hospital-administered IV diuretics, empowering self-care and reducing fluid overload hospitalizations. |
| 27 February 2025 | Teleflex, Inc. | Teleflex entered into a definitive agreement to acquire the Vascular Intervention business of BIOTRONIK SE & Co. KG. | The acquisition strengthens Teleflex's global interventional cardiology portfolio and expands its operational scale in cardiovascular treatment solutions. |
Congestive Heart Failure (CHF) Treatment Devices Market Scope: Inquire before buying
| Congestive Heart Failure (CHF) Treatment Devices Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2034 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | US $ 4.17 Mn. |
| Forecast Period 2026 to 2034 CAGR: | 5.5% | Market Size in 2034: | US $ 6.75 Mn. |
| Segments Covered: | by Product | Ventricular Assist Devices LVAD RVAD BiVAD Counter Pulsation Device Implantable Cardioverter Defibrillators Transvenous ICD Subcutaneous ICD Pacemakers Implantable External |
|
| by End-Users | Hospitals Ambulatory Care Centers Others |
||
Congestive Heart Failure (CHF) Treatment Devices Market, by Region
North America (United States, Canada, and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, ASEAN, Indonesia, Philippines, Malaysia, Vietnam, Thailand, ASEAN, Rest of Asia Pacific)
Middle East & Africa (South Africa, GCC, Nigeria, Rest of ME&A)
South America (Brazil, Argentina, Rest of South America)
Congestive Heart Failure (CHF) Treatment Devices Market, Key Players:
The Global Congestive Heart Failure (CHF) Treatment Devices refers to the worldwide industry encompassing the manufacturing, distribution, and sale of medical hardware used to manage, support, or correct heart failure. This market includes mechanical and electronic systems designed to assist heart pumping, regulate rhythms, and improve patient survival rates.
| Company Name | Headquarters | Core Competencies |
| Medtronic plc | Dublin, Ireland | Ventricular assist devices, cardiac rhythm management, implantable cardiac devices and heart-failure therapies |
| Abbott Laboratories | Abbott Park, Illinois, USA | Cardiac devices, CRT, pacemakers, implantable devices and heart-failure monitoring |
| Boston Scientific Corporation | Marlborough, Massachusetts, USA | Cardiac rhythm management, implantable devices and heart-failure/interventional cardiovascular technologies |
| Johnson & Johnson / Abiomed | New Brunswick, New Jersey, USA | Mechanical circulatory support, Impella heart pumps and cardiovascular devices |
| LivaNova plc | London, UK | Cardiac surgery systems, cardiopulmonary support and neuromodulation technologies |
| Biotronik SE & Co. KG | Berlin, Germany | Pacemakers, ICDs, CRT systems and cardiac monitoring |
| Berlin Heart GmbH | Berlin, Germany | Ventricular assist devices and mechanical circulatory support |
| Jarvik Heart, Inc. | New York, USA | Implantable ventricular assist devices and mechanical circulatory support |
| ReliantHeart, Inc. | Houston, Texas, USA | Ventricular assist devices and heart-failure monitoring/control systems |
| MicroPort Scientific Corporation | Shanghai, China | Cardiac rhythm management, cardiovascular devices and interventional cardiology |
| Lepu Medical Technology (Beijing) Co., Ltd. | Beijing, China | Cardiovascular intervention, cardiac devices and heart-failure-related technologies |
| ZOLL Medical Corporation | Chelmsford, Massachusetts, USA | Cardiac resuscitation, wearable defibrillation, monitoring and heart-failure technologies |
| EBR Systems, Inc. | Sunnyvale, California, USA | Wireless cardiac resynchronization therapy systems |
| CorWave SA | Paris, France | Implantable left ventricular assist devices and mechanical circulatory support |
| Magenta Medical Ltd. | Caesarea, Israel | Transcatheter heart pumps and temporary mechanical circulatory support |
| Syncardia Systems, LLC | Tucson, Arizona, USA | Total artificial heart and mechanical circulatory support |
| Oscor Inc. | Palm Harbor, Florida, USA | Cardiac pacing, electrophysiology and cardiovascular devices |
| OSYPKA AG | Rheinfelden, Germany | Cardiac surgery and interventional cardiovascular devices |
| Calon Cardio-Technology Ltd. | Caerphilly, UK | Implantable ventricular assist devices and mechanical circulatory support |
Frequently Asked Questions:
1. Which region has the largest share in Global Congestive Heart Failure (CHF) Treatment Devices Market?
Ans: North America region held the highest share in 2025.
2. What is the growth rate of Global Congestive Heart Failure (CHF) Treatment Devices Market?
Ans: The Global Congestive Heart Failure (CHF) Treatment Devices Market is growing at a CAGR of 5.5% during forecasting period 2026-2034.
3. What is scope of the Global Congestive Heart Failure (CHF) Treatment Devices Market report?
Ans: Global Congestive Heart Failure (CHF) Treatment Devices Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global Congestive Heart Failure (CHF) Treatment Devices Market?
Ans: The important key players in the Global Congestive Heart Failure (CHF) Treatment Devices Market are – Boston Scientific Corporation, Medtronic PLC, Abiomed, Inc., HeartWare International, Inc., Jarvik Heart, Inc., LivaNova PLC, ReliantHeart Inc., Biotronik SE & Co., KG, St. Jude Medical, Berlin Heart GmbH, Teleflex, Inc., Abbott, Edwards Lifesciences Corporation, Johnson & Johnson Services, Inc, MicroPort Scientific Corporation, and Mayo Foundation
5. What is the study period of this Market?
Ans: The Global Congestive Heart Failure (CHF) Treatment Devices Market is studied from 2020 to 2034.